Opthea announces Australian trial sites for its novel wet AMD treatment
Melbourne-based biopharmaceutical company Opthea has opened clinical trial sites in Australia, including in East Melbourne and Rowville, for patients to ...
Tag: phase 3
Opthea treats first patient in Phase 3 nAMD trial
The first patient in the Phase 3 clinical trial of a Melbourne-based drug company’s novel therapy for neovascular age-related macular ...
Presbyopia eye drop in final stage of clinical development
An ophthalmic pharmaceutical company has commenced two Phase 3 clinical studies to evaluate its eye drop candidate for presbyopia. Approximately ...
Roche’s faricimab meets primary endpoint in DME trial
Swiss drug giant Roche is poised to pursue regulatory clearance for its new faricimab antibody for diabetic macular edema (DME) ...
Tax credit strengthens Opthea’s balance sheet; follows AU$175m IPO on US exchange
Melbourne biopharmaceutical company Opthea has received an $8.5 million research and development (R&D) tax credit from the Australian tax authority ...
Opthea meets US and European regulators over Phase 3 trial
A Melbourne-based drug company is one step closer to starting Phase 3 clinical trials and pre-commercial development of its novel ...